SGLT2 Inhibition, Diabetes and CVD: Where does this fit in CV risk management?
Meeting report with video, highlights and slides of PACE-CME symposium held at ESC 2016 in Rome
Episodes 1-3 of 3
- SGLT2 Inhibition, Diabetes and CVD: Where does this fit in CV risk management?Challenging cardiovascular risk in diabetes: ready for a new approach?
John Deanfield, MD
- SGLT2 Inhibition, Diabetes and CVD: Where does this fit in CV risk management?HF & Diabetes: SGLT2 inhibition a paradigm shift?
John McMurray, MD
- SGLT2 Inhibition, Diabetes and CVD: Where does this fit in CV risk management?Overview of SGLT-2 inhibitors in T2DM management: current position & future promise
Silvio Inzucchi, MD
